Case Details
- Citation: [2022] SGHC 78
- Title: Combe International Ltd v Dr August Wolff GmbH & Co KG Arzneimittel
- Court: High Court of the Republic of Singapore
- Tribunal Appeal No: Tribunal Appeal No 22 of 2021
- Date of Judgment: 7 April 2022
- Judge: Lee Seiu Kin J
- Date of Hearing: 4 February 2022
- Plaintiff/Applicant: Combe International Ltd
- Defendant/Respondent: Dr August Wolff GmbH & Co KG Arzneimittel
- Legal Area: Intellectual Property — Trademarks (Opposition)
- Statute(s) Referenced: Trade Marks Act (Cap 332, 2005 Rev Ed) (“TMA”)
- Key Provisions: ss 8(2)(b), 8(7)(a), and (unappealed) ss 8(4)(b)(i) and 8(4)(b)(ii)
- Prior Proceedings Mentioned: (i) PAR invalidation decision; (ii) appeal dismissed by Hoo Sheau Peng J in Dr August Wolff GmbH & Co KG Arzneimittel v Combe International Ltd [2021] 4 SLR 626; (iii) IP Adjudicator decision: Dr August Wolff GmbH & Co KG Arzneimittel v Combe International Ltd [2021] SGIPOS 10
- Judgment Length: 35 pages, 9,488 words
- Cases Cited (as provided): [2016] SGIPOS 8; [2017] SGIPOS 7; [2018] SGIPOS 1; [2021] SGHC 165; [2021] SGIPOS 10; [2021] SGIPOS 13; [2022] SGHC 78
Summary
This case concerns a trademark opposition and subsequent appeal arising from the long-running dispute between Combe International Ltd (“Combe”) and Dr August Wolff GmbH & Co KG Arzneimittel (“Dr Wolff”). Combe owns earlier “VAGISIL” marks used for feminine care products. Dr Wolff sought to register the mark “VAGISAN” (and later a revised mark “Dr. Wolff’s VAGISAN”) for goods in Class 3 and Class 5, which include cosmetics/personal care and pharmaceutical or sanitary products for medical purposes.
After Combe successfully invalidated Dr Wolff’s earlier “VAGISAN” registration, Dr Wolff revised the mark by adding “Dr. Wolff’s” and reapplied. Combe opposed the new application. The IP Adjudicator (“IPA”) rejected Combe’s opposition on all pleaded grounds. Combe appealed to the High Court, challenging only the IPA’s findings under s 8(2)(b) of the Trade Marks Act and s 8(7)(a) (passing off). The High Court dismissed the appeal, holding that the marks were not sufficiently similar (including when the distinctiveness of the earlier mark was considered) and that the passing off ground was not made out.
What Were the Facts of This Case?
Combe was founded in 1949 and developed a portfolio of in-house brands, including “VAGISIL” products for feminine care. Combe held multiple registered “VAGISIL” marks: T9804752H, T9804751Z, T0813410H, and T1112897J. Three of these registrations covered goods in either Class 3 or Class 5, aligning with the broad category of intimate care products and related sanitary or medical-purpose goods.
Dr Wolff is part of the Dr Wolff Group, a family business founded in 1905. The group researches, manufactures, and markets dermatological, medicinal, and cosmetic products distributed internationally. The mark “VAGISAN” was conceived by Dr Wolff in 1994 as a portmanteau of “vagina” and “sanitas” (health). Dr Wolff sells intimate care products for women under the “VAGISAN” mark in multiple countries, including Austria, Malaysia, and the United Kingdom.
Prior to the present appeal, there were already disputes between the parties about Dr Wolff’s use of “VAGISAN”. Combe had successfully invalidated Dr Wolff’s registration of “VAGISAN” in Singapore. Dr Wolff then attempted to avoid further litigation by revising the mark: it added “Dr Wolff’s”, which is both the founder’s surname and an existing trademark in Singapore, and filed an application on 25 May 2018 to register the revised mark (the “Application Mark”) in both Class 3 and Class 5. IPOS accepted and published the application for opposition purposes on 7 December 2018.
Combe filed an opposition on 8 April 2019 relying on ss 8(2)(b), 8(4)(b)(i), 8(4)(b)(ii), and 8(7)(a) of the TMA. The IPA dismissed the opposition. In particular, for the s 8(2)(b) ground, the IPA found that the Application Mark and Combe’s “VAGISIL” marks were dissimilar. For the s 8(4) grounds (not appealed), the IPA held that Combe’s evidence did not establish that the “VAGISIL” marks were well known to the relevant sector as of 19 March 2012, and that inconsistent sales figures suggested the marks had not become well known since then. For the s 8(7)(a) ground, the IPA held that passing off by misrepresentation was not established.
Combe appealed the IPA’s decision. Notably, Combe did not appeal the IPA’s findings under ss 8(4)(b)(i) and 8(4)(b)(ii). The appeal therefore focused on whether the IPA erred in its s 8(2)(b) analysis (including distinctiveness, dominance of elements, and visual/aural/conceptual similarity) and whether the IPA erred in rejecting the passing off ground under s 8(7)(a).
What Were the Key Legal Issues?
The central issue under s 8(2)(b) of the TMA was whether the Application Mark was similar to Combe’s earlier “VAGISIL” marks such that, given the similarity of goods (which was not disputed), there would be a likelihood of confusion among the relevant public. The High Court approached this as a structured inquiry: first, similarity of the marks and similarity of goods; and second, likelihood of confusion.
Within the marks-similarity inquiry, the dispute narrowed to how the court should assess (i) the distinctiveness of the earlier mark and how it affects the similarity analysis; (ii) the role of the added element “Dr. Wolff’s” in the Application Mark; (iii) whether “VAGISAN” or “Dr. Wolff’s” was the dominant element; and (iv) whether the marks were visually, aurally, and conceptually similar. Combe argued that the IPA’s findings on each of these sub-issues were erroneous.
The second key issue concerned s 8(7)(a), which incorporates the common law tort of passing off. The question was whether Combe had established the elements of passing off, particularly misrepresentation leading to damage. The IPA had found that misrepresentation was not established; Combe challenged that conclusion.
How Did the Court Analyse the Issues?
Because this was an appeal from the IPA’s decision, the High Court applied the procedural framework for “rehearing” under the Rules of Court. The court emphasised that there is no threshold requirement to show a material error of fact or law before appellate intervention is warranted. Trade mark opposition proceedings are treated as involving legal correctness and entitlement rather than discretionary judgment. Further, because opposition hearings do not involve trial-style oral evidence, the appellate court is in as good a position as the IPA to evaluate the facts based on the record.
On the substantive law, the court adopted a step-by-step approach to s 8(2)(b), consistent with established authority. It first considered whether the marks were similar (and whether the goods/services were similar). Here, the parties did not dispute similarity of goods. The court therefore focused on whether the Application Mark and the “VAGISIL” marks were similar, before moving to the likelihood of confusion analysis.
In assessing similarity, the court reiterated that the inquiry is directed towards substantive similarity and comprises three aspects: visual, aural, and conceptual similarities. However, the court cautioned that the analysis is not a mechanical “checklist”; rather, the three aspects guide the overall assessment. Importantly, distinctiveness of the earlier mark is not treated as a separate step. Instead, it is integrated into the visual, aural, and conceptual analysis, affecting how the marks are perceived and compared.
Applying these principles, the court examined the role of the added element “Dr. Wolff’s” in the Application Mark. Combe’s arguments included that “Dr. Wolff’s” was distinctive and at least equally distinctive as “VAGISAN”, that the dominant element was not “VAGISAN”, and that this affected the overall similarity assessment. The court’s reasoning (as reflected in the judgment’s structure) addressed visual, aural, and conceptual similarity in turn, and then considered whether, taking all factors together, the marks were sufficiently dissimilar to negate a likelihood of confusion.
On visual similarity, the court considered how the marks would be perceived in the marketplace, focusing on the overall impression created by the composite mark “Dr. Wolff’s VAGISAN” compared with the earlier “VAGISIL” marks. The presence of “Dr. Wolff’s” was treated as a meaningful differentiating feature rather than a negligible addition. The court therefore concluded that the visual impression did not align closely enough to support a finding of similarity.
On aural similarity, the court analysed how the marks would likely be pronounced by consumers. The added “Dr. Wolff’s” component changed the sound and rhythm of the Application Mark, and the court treated this as affecting the overall aural comparison. While both marks share a family resemblance in the “VAGI-” starting sound, the court’s conclusion was that the composite mark’s pronunciation would not be sufficiently close to create confusion.
On conceptual similarity, the court considered the meanings conveyed by the marks. “VAGISAN” was understood as a portmanteau associated with intimate health, while “VAGISIL” was associated with Combe’s brand identity. The court also considered how the “Dr. Wolff’s” element would anchor the Application Mark to Dr Wolff’s corporate/founder identity, thereby reducing the likelihood that consumers would perceive the marks as conceptually linked.
Having concluded that the marks were dissimilar, the court found that the s 8(2)(b) requirement of similarity (and the consequent likelihood of confusion) was not satisfied. The court’s reasoning reflects the logic that where the marks do not meet the similarity threshold, the confusion inquiry cannot succeed even if the goods are similar.
For s 8(7)(a), the court upheld the IPA’s finding that passing off by misrepresentation was not established. The analysis turned on whether Combe could show that Dr Wolff’s use of the Application Mark would misrepresent a connection with Combe’s goodwill such that consumers would be misled. The court agreed with the IPA that the evidence and the overall comparison of the marks did not support a finding of misrepresentation.
What Was the Outcome?
The High Court dismissed Combe’s appeal. The court upheld the IPA’s decision allowing the registration of the Application Mark, meaning that Dr Wolff’s revised mark “Dr. Wolff’s VAGISAN” remained on the register (subject to the procedural posture of the opposition and any further appeals).
Practically, the decision confirms that adding a distinctive branding element (here, “Dr. Wolff’s”) can be sufficient to overcome an opposition under s 8(2)(b) where the overall mark comparison—visually, aurally, and conceptually—does not show substantive similarity, even when the goods are similar and the earlier mark has some degree of distinctiveness.
Why Does This Case Matter?
This decision is useful for practitioners because it illustrates how Singapore courts apply the structured s 8(2)(b) framework in trademark opposition appeals: similarity of goods is assessed first (often straightforward where parties agree), but the decisive battleground is frequently marks similarity. The court’s emphasis that distinctiveness is integrated into the similarity analysis reinforces that the earlier mark’s strength does not automatically translate into a finding of similarity; it affects perception, but the court still evaluates the overall impression.
The case also highlights the significance of composite marks and the “dominant element” debate. Where an applicant adds a house mark or founder identifier, the court will consider whether that addition meaningfully alters the overall visual, aural, and conceptual impression. In this case, the court accepted that “Dr. Wolff’s” was not merely ornamental and could prevent the marks from being treated as similar.
For passing off under s 8(7)(a), the case underscores that misrepresentation is not established by abstract similarity alone. Even where there is some overlap in how consumers might think about intimate care products, the court will look for a realistic likelihood that consumers would be misled about commercial origin or affiliation. The decision therefore serves as a caution to brand owners relying on passing off: the evidential and analytical link between mark use and misrepresentation must be made out.
Legislation Referenced
- Trade Marks Act (Cap 332, 2005 Rev Ed), in particular:Section 8(2)(b)
- Section 8(7)(a)
- Sections 8(4)(b)(i) and 8(4)(b)(ii) (not appealed)
Cases Cited
- Ceramiche Caesar SpA v Caesarstone Sdot-Yam Ltd [2017] 2 SLR 308
- Future Enterprises Pte Ltd v McDonald’s Corp [2007] 2 SLR(R) 845
- Ceramiche Caesar SpA v Caesarstone Sdot-Yam Ltd [2017] 2 SLR 308
- Ho Soo Fong v Standard Chartered Bank [2007] 2 SLR(R) 181
- Courts (Singapore) Pte Ltd v Big Box Corp Pte Ltd [2018] 5 SLR 312
- The Polo/Lauren Co, LP v Shop In Department Store Pte Ltd [2006] 2 SLR(R) 690
- Staywell Hospitality Group Pty Ltd v Starwood Hotels & Resorts Worldwide, Inc [2014] 1 SLR 911
- Richemont International SA v Goldlion Enterprise (Singapore) Pte Ltd [2006] 1 SLR(R) 401
- Hai Tong Co (Pte) Ltd v Ventree Singapore Pte Ltd [2013] 2 SLR 941
- Digi International v Teraoka Seiko Co, Ltd [2021] SGHC 165
- Dr August Wolff GmbH & Co KG Arzneimittel v Combe International Ltd [2021] 4 SLR 626
- Dr August Wolff GmbH & Co KG Arzneimittel v Combe International Ltd [2021] SGIPOS 10
- Combe International Ltd v Dr August Wolff GmbH & Co KG Arzneimittel [2022] SGHC 78 (this appeal)
- [2016] SGIPOS 8
- [2017] SGIPOS 7
- [2018] SGIPOS 1
- [2021] SGIPOS 10
- [2021] SGIPOS 13
Source Documents
This article analyses [2022] SGHC 78 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.